GoAI
Get started
Envoy Medical, Inc. logo

Envoy Medical, Inc.

COCH

NASDAQHealthcareMedical - Devices

Open in GoAI

Latest quote

$0.7422

−$0.0004 · -0.05%

Aug 21, 3:55 PM ET

COCH company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

40

Expensive

Momentum

35

Weakening

Sentiment

43

Mixed

Risk resilience

21

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Envoy Medical, Inc. is a healthcare company dedicated to developing innovative medical technologies that address the full spectrum of hearing loss. Its diverse product portfolio includes conventional hearing aids, Esteem middle ear implants, bone conduction devices, and Acclaim cochlear implants. Established in 1995, the company originally operated as St. Croix Medical, Inc. before officially rebranding to Envoy Medical, Inc. in December 2004. Envoy Medical, Inc. is headquartered in White Bear Lake, Minnesota.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Brent T. Lucas
Listed since
Apr 29, 2021
Employees
43

Market position

Volume
60.43K
0.19× average
Average volume
310.05K
Average daily volume
Market cap
15.6M USD
Beta
1.89
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-1.11×
P/B (TTM)
23.62×
P/S (TTM)
75.36×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-385.51%
Operating margin
-11411.11%
Net margin
-11304.83%

Financial health

Debt / equity
0.25×
Altman Z-score
-21.2
Piotroski F-score
3 of 9

Earnings

EPS beat rate
27%
3 beats, 8 misses, 0 met estimates
Average EPS surprise
-16.60%
11 comparable reports
Latest EPS result
-0.07
Estimate -0.08 · Beat by 12.50%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.06-0.2-0.35-0.49Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 28, 2025: actual -0.45, estimate -0.33, surprise -36.36%, Miss. Q2 2025, reported May 1, 2025: actual -0.29, estimate -0.35, surprise +17.14%, Beat. Q3 2025, reported Jul 31, 2025: actual -0.32, estimate -0.29, surprise -10.34%, Miss. Q4 2025, reported Nov 10, 2025: actual -0.35, estimate -0.27, surprise -29.63%, Miss. Q1 2026, reported Mar 23, 2026: actual -0.26, estimate -0.24, surprise -8.33%, Miss. Q2 2026, reported May 11, 2026: actual -0.11, estimate -0.14, surprise +21.43%, Beat. Q3 2026, reported Aug 10, 2026: actual -0.07, estimate -0.08, surprise +12.50%, Beat. Q4 2026, reported Nov 9, 2026: actual —, estimate -0.07, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates105.6K78.9K52.2K25.5KQ1 '25No estimateQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 28, 2025: actual 42K USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 1, 2025: actual 46K USD, estimate 65K USD, surprise -29.23%, Miss. Q3 2025, reported Jul 31, 2025: actual 78K USD, estimate 66.25K USD, surprise +17.74%, Beat. Q4 2025, reported Nov 10, 2025: actual 42K USD, estimate 60K USD, surprise -30.00%, Miss. Q1 2026, reported Mar 23, 2026: actual 100K USD, estimate 30K USD, surprise +233.33%, Beat. Q2 2026, reported May 11, 2026: actual 39K USD, estimate 100K USD, surprise -61.00%, Miss. Q3 2026, reported Aug 10, 2026: actual 51K USD, estimate 50K USD, surprise +2.00%, Beat. Q4 2026, reported Nov 9, 2026: actual —, estimate 50K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$2.00

166.67% upside
Past 12 months12-month forecastHigh $2.00Average $2.00Low $2.00

Rating distribution

3 ratings

Limited analyst sample: 3 ratings. Interpret the distribution with caution.

Strong buy00%
Buy3100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

3 institutions
Lake StreetmaintainBuy

COCH peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research COCH

research.disclaimer